Literature DB >> 18287969

Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus.

Ling Yi Chang1, Donald McCurnin, Bradley Yoder, Phillip W Shaul, Ronald I Clyman.   

Abstract

Premature newborn baboons [125 d (67%) gestation], exposed to a moderate-size patent ductus arteriosus (PDA) [pulmonary-to-systemic blood-flow-ratio (Qp/Qs) = 1.8] for 14 d, have impaired pulmonary function and arrested alveolar development and surface area when compared with age matched fetuses (140 d gestation). Pharmacologic closure of the PDA reduces the detrimental effects of preterm delivery on pulmonary function and surface area. We used preterm baboons (delivered at 125 d gestation and ventilated for 14 d) to study the effects of surgical PDA ligation on pulmonary function and alveolar surface area. After ligation (on day of life 6), ligated animals had lower Qp/Qs ratios [Qp/Qs (ligated, n = 10) = 1.00 +/- 0.04; (nonligated, n = 12) = 2.05 +/- 0.17; mean +/- SD] and higher systemic blood pressures than nonligated control animals. Ventilation and oxygenation indices did not differ between the groups, during either the pre- or postoperative periods. Alveolar surface area measurements were made by digital image analysis and compared with measurements made from fetal lungs at 125 d (n = 6) and 140 d (n = 7) gestation. PDA ligation failed to improve the postnatal arrest in alveolar surface area. In contrast with pharmacologic closure of the PDA, surgical closure failed to improve either pulmonary function or alveolar surface area in baboons with a moderate PDA shunt.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287969     DOI: 10.1203/PDR.0b013e318163a8e4

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

1.  Patent ductus arteriosus in premature infants: A never-closing act.

Authors:  Bernard Thébaud; Thierry Lacaze-Mazmonteil
Journal:  Paediatr Child Health       Date:  2010-05       Impact factor: 2.253

2.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

3.  Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.

Authors:  Melissa Liebowitz; Ronald I Clyman
Journal:  J Pediatr       Date:  2017-04-07       Impact factor: 4.406

4.  Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

Authors:  Peter Gal
Journal:  J Pediatr Pharmacol Ther       Date:  2009-01

Review 5.  The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.

Authors:  Ronald I Clyman
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

6.  Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment.

Authors:  Nami Jhaveri; Anita Moon-Grady; Ronald I Clyman
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

7.  Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons.

Authors:  Nahid Waleh; Donald C McCurnin; Bradley A Yoder; Philip W Shaul; Ronald I Clyman
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

Review 8.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

9.  The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial.

Authors:  Ronald Clyman; George Cassady; James K Kirklin; Monica Collins; Joseph B Philips
Journal:  J Pediatr       Date:  2009-03-25       Impact factor: 4.406

Review 10.  Animal models of bronchopulmonary dysplasia. The preterm baboon models.

Authors:  Bradley A Yoder; Jacqueline J Coalson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-03       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.